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The aggressiveness of malignant melanoma is associated with differential expression of CXCL-8 and its receptors, CXCR1 and
CXCR2. However, the precise functional role of these receptors in melanoma progression remains unclear. In this study, we
investigate the precise functional role of CXCR1 and CXCR2 in melanoma progression. CXCR1 or CXCR2 were stably
overexpressed in human melanoma cell lines, SBC-2 (non-tumourigenic) and A375P (low-tumourigenic) exhibiting low endogenous
expression of receptors. Functional assays were performed to study the resulting changes in cell proliferation, motility and invasion,
and in vivo tumour growth using a mouse xenograft model. Our data demonstrated that CXCR1- or CXCR2-overexpressing SBC-2
and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2
overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo.
Immunohistochemical analyses showed significantly increased tumour cell proliferation and microvessel density and reduced
apoptosis in tumours generated from CXCR1- or CXCR2-overexpressing melanoma cells. CXCR1- or CXCR2-induced modulation
of melanoma cell proliferation and migration was observed to be mediated through the activation of ERK1/2 phosphorylation.
Together, these studies demonstrate that CXCR1 and CXCR2 play essential role in growth, survival, motility and invasion of human
melanoma.
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Melanoma is the most common skin cancer associated with
significant mortality (Lee, 1992). According to an estimate by
American Cancer Society, 62480 new cases of melanoma will be
diagnosed in 2008 and 8420 people will die due to this disease in the
United States (Jemal et al, 2008). Although early disease can be
treated by surgery and a minor benefit noted with adjuvant therapy,
no effective treatment is available for the advanced disease (Herlyn,
2006; Lee, 1992, 1996). Hence, an in-depth understanding of the
biology of melanoma progression is highly required.
CXCL-8, a member of the CXC chemokine family, has been
reported to induce migration, stimulate angiogenesis and promote
tumour cell growth in melanoma and other malignancies
(Matsushima and Oppenheim, 1989; Wang et al, 1990; Koch
et al, 1992; Schadendorf et al, 1993; Youngs et al, 1997; Miyamoto
et al, 1998; Bar-Eli, 1999; Singh and Varney, 2000; Li et al, 2002).
CXCL-8 is a multifunctional cytokine/growth factor that binds to
two high-affinity receptors: type A CXCL-8 receptor (IL-8RA/IL-
8RI or CXCR1) and type B CXCL-8 receptor (IL-8RB/IL-8RII or
CXCR2; Holmes et al, 1991; Murphy and Tiffany, 1991). Although
CXCR2 binds with high affinity to CXCL-8 and other CXC
chemokines such as CXCL-6, CXCL-5, CXCL-7 and
CXCL-1, CXCR1 is less promiscuous and binds only to CXCL-8
(Matsushima and Oppenheim, 1989; Oppenheim et al, 1991; Miller
and Krangel, 1992). Both these receptors have been implicated in
the migration of neutrophils, monocytes and lymphocytes (Holmes
et al, 1991; Murphy and Tiffany, 1991; Peiper et al, 1995; Moser
and Loetscher, 2001). CXCR1 and CXCR2 share a high degree of
sequence similarity (75.8% in amino-acid sequence), but differ
within the extracellular and intracellular loops and the NH2- and
COOH-terminal domains (Jones et al, 1995).
The expression of CXCL-8 in melanoma has been shown to
correlate positively with disease progression (Singh et al, 1994;
Ugurel et al, 2001). The aggressiveness of malignant melanoma is
attributed, in part, to the expression of CXCL-8 and its receptors,
CXCR1 and CXCR2 (Varney et al, 2006). In addition to melanoma
cells, both CXCR1 and CXCR2 are differentially expressed on
endothelial cells (Clark-Lewis et al, 1993; Addison et al, 2000; Li
et al, 2002, 2003; Varney et al, 2003). Several studies have
implicated CXCR1 and CXCR2 as important players in tumour
progression (Brat et al, 2005; Murphy et al, 2005; Kline et al, 2007).
We have also shown that neutralisation of CXCR1 or CXCR2
affects cell proliferation and migration, indicating the involvement
of these receptors in altered cellular responses (Varney et al, 2003).
However, the functional significance of CXCR1 and CXCR2 and its
ligand CXCL-8 in melanoma progression remains unclear.
In this study, we hypothesised that CXCR1 and CXCR2 regulate
melanoma tumour growth and progression. We have performed
in vitro and in vivo functional assays to provide direct evidence for
multiple overlapping roles of CXCR1 and CXCR2 in melanoma
growth, tumourigenesis, motility and invasion in two cell line models
(SBC-2, non-tumourigenic and A375P, low-tumourigenic).
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Cell lines, culture conditions and stable transfection
The human melanoma SBC-2 (non-tumourigenic) and A375P (low-
tumourigenic) cell lines were cultured in RPMI-1640 or Dulbecco’s
Modified Eagle Medium (MediaTech, Herndon, VA, USA) at 371C
with 5% CO2 in humidified atmosphere. Culture media were
supplemented with 5% fetal bovine serum (FBS; MediaTech), 1% L-
glutamine (MediaTech), 1% vitamin solution (MediaTech) and
gentamycin (Invitrogen, Carlsbad, CA, USA). Plasmids (pcDNA 3.1/
Neo) carrying CXCR1 or CXCR2 cDNA were obtained from the
University of Missouri cDNA Resource Center, Rolla, MO, USA.
The insert sequence and orientation were confirmed by sequencing
the clones. SBC-2 and A375P cells (5 10
5 cells per dish) were
seeded in 100mm culture dishes (Falcon, Lincoln Park, NJ, USA) in
complete medium. Twenty-four hours later (at 60–80% conflu-
ence), the cells were transfected with pcDNA3.1/Neo (SBC-2-
control or A375P-control), pcDNA3.1/Neo-CXCR1 (SBC-2-CXCR1
or A375P-CXCR1) or pcDNA3.1/Neo-CXCR2 (SBC-2-CXCR2 or
A375P-CXCR2) plasmids using Lipofectamine (Invitrogen) follow-
ing the manufacturers protocol. Forty-eight hours later, the cells
were switched to a selective medium containing Geneticin (G418;
400–800mgml
 1; Invitrogen). Resistant pooled populations were
selected and maintained in medium supplemented with G418.
RNA isolation and RT–PCR analysis
Total RNA was isolated using Trizol reagent (Invitrogen). To
confirm the ectopic expression of CXCR1 and CXCR2 mRNA, we
performed reverse transcriptase-based PCR (RT–PCR) analysis,
using vector-specific (forward) and receptor-specific (reverse)
primers. Briefly, cDNA was synthesised from 5mg total RNA using
SuperScript II Reverse Transcriptase (Invitrogen) and oligo(dT)
primer. Two microlitres of first strand cDNA (1:10 dilution) was
amplified using the following primers: pcDNA 3.1/Neo, 50-CTAG
CGTTTAAACTTAAGCTTGGTA-30 (forward), CXCR1, 50-AGGGC
AGGGACAGATTCATAG-30 (reverse) and CXCR2, 50-GGGCCAGGA
GCAAGGACAGA-30 (reverse); control GAPDH, 50-ACGCATTTG
GTCGTATTGGG-30 (forward) and GAPDH, 50-TGATTTTGGAGGG
ATCTCGC-30 (reverse). Amplified products were resolved through
a 1.5% agarose gel containing ethidium bromide and analysed
using an Alpha Imager gel documentation system (AlphaInnotech,
San Leandro, CA, USA).
Western blot analysis
Cells were processed for protein extraction and western blotting
using standard procedures. Briefly, the cells were washed twice
with PBS and scraped in Triton X-100 buffer (1% Triton X-100,
50mmoll
 1 TBS (pH 7.4), 10mmoll
 1 EDTA with protease
inhibitors (Roche Diagnostics, Mannheim, Germany) and phos-
phatase inhibitors (5mM NaF and 5mM Na3VO4; Sigma Chemicals,
St Louis, MO, USA)). Cell lysates were passed through the needle
syringe to facilitate the disruption of the cell membranes and were
centrifuged at 14000r.p.m. for 20min at 41C, and supernatant
were collected. The proteins (50mg) were resolved by electro-
phoresis on 8% SDS–PAGE and transferred onto a polyvinylidene
difluoride membrane. Subsequently, the membranes were sub-
jected to standard immunodetection procedure using specific
antibodies: anti-CXCR1 and anti-CXCR2 (1:50, mouse mono-
clonal; R&D Systems, Minneapolis, MN, USA); anti-GAPDH
(1:1000, rabbit monoclonal; Cell Signaling Technology, Beverly,
MA, USA); pERK1/2 and ERK1/2 (1:1000, rabbit polyclonal; Cell
Signaling Technology). Secondary horseradish peroxidase-conju-
gated antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were used at 1:2000 dilution. To examine ERK1/2 mitogen-
activated protein kinase (MAPK) signalling, cells were treated for
1h with 20mM PD98059 (Calbiochem, Gibbstown, NJ, USA), a
specific inhibitor of ERK1/2 MAP kinase. All the blots were
processed with ECL Plus Western Blotting detection kit (GE
Healthcare, Piscataway, NJ, USA), and the signal was detected by a
Typhoon 9410 Variable Mode Imager.
In vitro cell growth assay
Cells were seeded in 96-well plates at low density (5000 cells per
well (SBC-2-transfected); 1000 cells per well (A375P-transfected)).
Following overnight adherence, cells were incubated with media
alone or medium containing different serum concentrations, with
or without CXCL-8 (10ngml
 1) for 72h. Cell proliferation was
determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide, a tetrazole) assay as previously described
(Singh and Varney, 1998; Li et al, 2001). Growth increase was
calculated as percent (%)¼[{(A/B) 1} 100], where A and B are
the absorbance of treated (CXCL-8-stimulated) and untreated cells
(media alone), respectively.
Cell motility and invasion assay
To investigate the effect of overexpression of CXCR1 or CXCR2 on
cell migration, cells (1 10
6 cells per well) in serum-free media
were plated in the top chamber of non-coated polyethylene
terephthalate membranes (six-well insert; 8mm pore size;
Becton Dickinson, Franklin Lakes, NJ, USA). For invasion, cells
(10000 cells per well) were plated onto Matrigel-coated transwell
chambers (24-well insert; 8mm pore size; Corning Costar Corp.,
Cambridge, MA, USA) in serum-free media. The bottom chamber
contained 1.0ml serum-free media with or without CXCL-8
(10ngml
 1). The cells were incubated for 24h at 371C and cells
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Figure 1 CXCR1 and CXCR2 expression in SBC-2 and A375P
melanoma cells. Cells were stably transfected with vector control, or with
vector containing CXCR1 or CXCR2 cDNA insert. (A) RT–PCR analysis
shows increased expression of CXCR1 or CXCR2 mRNA in selected
pooled clones. GAPDH was used as a control. (B) Western blotting
showing increased expression of CXCR1 and CXCR2 in overexpressing
melanoma cells as compared with control cells. GAPDH was used as a
loading control. This is a representative gel picture of at least three
experiments with similar results.
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sthat did not pass through the membrane pores were removed.
Migrated cells were stained using Hema 3 kit (Fisher
Scientific Company L.L.C., Kalamazoo, MI, USA) as per the
manufacturer’s instructions and counted in 10 random fields
(200 ). To study the role of MAPK signalling in cell migration,
transfected SBC-2 and A375P cells were treated with 20mM
PD98059 (Calbiochem MAPK) inhibitor for 1h. Cells were than
analysed for migration.
Tumour growth analysis
To test the tumourigenic capacity and growth kinetics, group of 5
nude mice (n¼5) were injected subcutaneously (s.c.) in the dorsal
flank with 3 10
6 cells (SBC-2-CXCR1, SBC-2-CXCR2 or SBC-2-
control) or 1 10
6 cells (A375P-CXCR1, A375P-CXCR2 or A375P-
control). Tumour volume was measured twice weekly with a
calliper and was calculated by using the formula p/6 (smaller
diameter)
2 (larger diameter). Mice were killed on day 45 (A375P-
group) and on day 75 (SBC-2-group) after tumour implantation.
All studies were done in accordance with the Institutional Animal
Use and Care Committee of the University of Nebraska Medical
Center. For histological examinations, tissues were fixed in zinc
fixative and embedded in paraffin.
Immunohistochemistry
Immunohistochemical analysis was performed as previously
described (Varney et al, 2006) using the following antibodies:
mouse monoclonal anti-proliferating cell nuclear antigen (PCNA;
1:40; Santa Cruz Biotechnology), mouse monoclonal anti-CXCR1
(1:100; R&D systems), mouse monoclonal anti-CXCR2 (1:50;
R&D systems) and mouse biotinylated GS-IB4 (isolectin from
Griffonia simplicifolia; 1:50; Vector Laboratories, Burlingame, CA, USA).
Tumour cell apoptosis was measured using terminal
deoxyribonucleotidyl transferase dUTP nick end labelling
(TUNEL). Briefly, tumour sections were deparaffinised by incuba-
tion in EZ-Dewax (Biogenex, San Ramon, CA, USA) and rinsed in
distilled water to remove residual EZ-Dewax. Following non-
specific blocking for 30min, sections were incubated with primary
antibodies overnight at 41C. Sections were then washed and
subsequently incubated at room temperature with the respective
biotinylated secondary antibodies (1:500 in PBS) for 45min,
except for GS-IB4. Immunoreactivity was visualised by incubation
with avidin–biotin complex and diaminobenzidine tetrahy-
drochloride substrate (Vector Laboratories). The sections were
observed and stained cells and vessels were counted microscopi-
cally (Nikon, Melville, NY, USA) using 5 5 reticle grid (Klarmann
Rulings, Litchfield, NH, USA).
Statistical analysis
All values are expressed as mean±s.e.m. Differences between
the groups were compared using the unpaired two-tailed t-test
in SPSS software (SPSS Inc., Chicago, IL, USA). In vivo analysis
was performed using Mann–Whitney U-test for significance. A P
value of equal or less than 0.05 was considered statistically
significant.
RESULTS
Isolation and characterisation of clones overexpressing
CXCR1 or CXCR2
To test the functional role of CXCR1 and CXCR2 in human
melanoma, SBC-2 and A375P melanoma cells were stably
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Figure 2 CXCR1 and CXCR2 expression enhances melanoma tumour growth. Stably transfected SBC-2 (3 10
6 cells in 0.1ml of HBSS) or A375P
(1 10
6 cells in 0.1ml of HBSS) cells were subcutaneously (s.c.) injected into the flank of nude mice. In SBC-2-group, tumour incidence represents the
number of tumours formed per number of injected mice and tumour volume on day 75 after tumour injection (A). For A375P-group tumour volume from
day 0 to day 45 (n¼5) (B). Growth of A375P-CXCR1 and A375P-CXCR2 increased significantly compared with A375P-control. Results are shown as
mean±s.e.m. *Significantly different from controls (Po0.05).
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stransfected with empty vector (pcDNA 3.1/Neo) or vector
containing CXCR1 or CXCR2 cDNA. G418-resistant clones derived
from the control vector, CXCR1- or CXCR2-transfected cells were
isolated, expanded and the stable overexpression of CXCR1 and
CXCR2 was determined in the pooled sublines by RT–PCR
(Figure 1A) and western blot (Figure 1B). The stable over-
expression of CXCR1 or CXCR2 in SBC2 and A375P cells
compared with vector control was also monitored by immunocy-
tochemical analyses (Supplementary Figure 1A). Receptor expres-
sion was observed on both the cell surface and cytoplasm. Results
of immunocytochemical analyses were consistent with the western
blot analysis, further confirming the stable overexpression of
CXCR1 or CXCR2.
Overexpression of CXCR1 or CXCR2 enhanced tumour
growth
To determine the role of CXCR1 or CXCR2 in melanoma tumour
growth, SBC2-transfected (SBC-2-CXCR1, SBC2-CXCR2 or SBC-2-
control) and A375P-transfected (A375P-CXCR1, A375P-CXCR2 or
A375P-control) cells were injected subcutaneously in nude mice
and monitored for tumour growth. Mice injected with SBC-2-
CXCR1 or SBC2-CXCR2 cell lines showed a palpable tumour
within 30 days after injection, whereas the mice injected with
A375P-CXCR1, A375P-CXCR2 or A375P-control cell lines showed
a tumour within a week. The mice injected with SBC-2-control did
not show any tumour formation as expected (Singh et al, 1995).
Mice injected with SBC-2-CXCR1 cells, had 60% tumour incidence,
whereas the mice with SBC-2-CXCR2 had 100% tumour incidence
(Figure 2A). In the A375P group (A375P-CXCR1, A375P-CXCR2 or
A375P-control), all the mice developed tumours. SBC-2-CXCR1
cells injected s.c. produced tumours with an average volume of
226.9±98.8mm
3, whereas, SBC-2-CXCR2 tumours had an average
volume of 465.8±58.8mm
3. Additionally, mice injected with
A375P-CXCR1 or A375P-CXCR2 cells exhibited significantly
enhanced tumour growth (2.6 to 2.9-fold, Po0.05) as compared
to A375P-control cells-injected mice (Figure 2B). Sustained
expression of CXCR1 and CXCR2 in tumour tissues was confirmed
by immunohistochemical staining (data not shown).
Increased proliferation and decreased apoptosis in CXCR1
or CXCR2 expressing melanoma tumours
As induced and enhanced tumour growth may be the result of
increasing proliferation or decreasing apoptosis, we examined the
contribution of these two processes by PCNA and TUNEL
immunostaining of tumours. As SBC-2-control did not form
tumours, no comparison in number of PCNA and TUNEL-positive
cells was done with SBC-2-CXCR1 or SBC-2-CXCR2 tumours.
Interestingly, a higher number of PCNA-positive compared
to TUNEL-positive cells was observed in SBC-2-CXCR1 and
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Figure 3 CXCR1 and CXCR2 expression enhances in vivo melanoma cell proliferation, survival and tumour neovascularisation. Immunohistochemical
staining for PCNA and TUNEL were analysed based on DAB staining as described in Materials and Methods. In SBC-2-group, tumours showed an imbalance
of PCNA to TUNEL-positive cells (A). For A375P-group PCNA (B, upper panel) and TUNEL (B, lower panel) positive cells were counted in 10 arbitrarily
selected fields at 200  magnification in a double-blinded manner and expressed as average number of cells per field view±s.e.m. Immunohistochemical
staining for microvessel using anti-GS-IB4 was analysed as described in Materials and Methods. Tumours from SBC-2 group were highly vascular (C). For
A375P tumours, quantification of microvessel density at 200  magnification in 10 random fields was examined. The values are average number of
immunostained positive cells±s.e.m. (D). *Significantly different from control (Po0.05).
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sSBC-2-CXCR2 tumours (Figure 3A). The average number of
PCNA-positive cells for A375P-CXCR1 (1.6-fold; Po0.05) and
A375P-CXCR2 (1.8-fold; Po0.05) were significantly higher as
compared to A375P-control tumours (Figure 3B, upper panel;
Supplementary Figure 2A). Similarly, the average number of
TUNEL-positive cells in A375P-CXCR1 (36%) and A375P-CXCR2
(32%) were significantly lower as compared to A375P-control
tumours (87%), demonstrating a 2.4-fold (A375P-CXCR1) and
2.7-fold (A375P-CXCR2) decrease compared to control tumours
(Figure 3B, lower panel; Supplementary Figure 2B).
Overexpression of CXCR1 or CXCR2 enhanced tumour
neovascularisation
Most solid tumours, including melanoma, require new blood vessel
formation to grow beyond a few millimetres in diameter (Folkman,
1995). Having examined the effect of overexpression of CXCR1 or
CXCR2 on tumourigenicity, we next examined their roles in
facilitating neovascularisation in vivo. The number of blood vessels
was compared in tumour tissues by immunohistochemical staining
using biotinylated isolectin B4 (GS-IB4). The average number of
blood vessels was counted, excluding necrotic areas. The tumours
from SBC2-CXCR1 and SBC-2-CXCR2 were highly vascular
(Figure 3C). We observed a 2.0-fold (A375P-CXCR1) and a 2.3-
fold (A375P-CXCR2) increase in the number of tumour blood
vessels as compared to the A375P-control tumours (Figure 3D).
CXCR1 or CXCR2 enhanced human melanoma cell growth,
motility and invasiveness in vitro
Having seen the observable differences in tumourigenicity, we next
performed in vitro assays to examine the effect of CXCR1 and
CXCR2 overexpression on the growth and malignant behaviour of
melanoma cells. Tumour cell growth was examined by MTT assay.
Both the cell line models (SBC-2 and A375P) resulted in a
progressive increase in growth in vitro assays (Figure 4A and B).
Our data also demonstrated a significant (Po0.05) increase in
CXCL-8-induced chemotaxis of SBC-2-CXCR1 (1.6-fold) or SBC-2-
CXCR2 (1.9-fold) cells as compared to the SBC-2-control cells
(Figure 5A). A375P-CXCR1 and A375P-CXCR2 cells also showed a
significant (Po0.05) increase in the number of migrating cells by
2.2- 2.9-fold as compared with A375P-control in an in vitro
migration assay (Figure 5B). Next, we examined whether the
increase in cell motility was also associated with the enhanced
invasive potential of these cells. Our results showed that the
number of invading cells in SBC-2-cells was 1.8-fold (SBC-2-
CXCR1) and 2.5-fold (SBC-2-CXCR2) higher as compared to SBC-
2-control cells (Figure 5C). Similarly, A375P cells were 2.1-fold
(A375P-CXCR1) and 2.7-fold (A375P-CXCR2) higher as compared
to the A375P-control cells (Figure 5D).
ERK1/2 mitogen-activated protein kinase pathway is
involved in CXCR1- or CXCR2-mediated melanoma cell
growth and motility
The MAP kinase pathway is important for growth, differentiation,
survival and migration (Dunn et al, 2005; Yoon and Seger, 2006).
CXCL-8 has already been shown to induce intracellular signalling
pathways activated by CXCR1 and CXCR2 by phosphorylation of
ERK1/2 MAP kinase (Venkatakrishnan et al, 2000; Prado et al,
2007). To explain the mechanism by which the CXCL-8-CXCR1/2
axis is involved in the growth and migration of melanoma cells, we
investigated the involvement of ERK1/2 MAP kinases. The
treatment of A375P (A375P-CXCR1 and A375P-CXCR2) cells with
CXCL-8 (10ngml
 1) induced ERK1/2 phosphorylation more
potently in comparison with the control cells and was maximal
by 30min (Figure 6A, left and middle panel). Furthermore,
treatment of the cells with PD98059 completely suppressed the
activation of ERK in the presence of CXCL-8 (Figure 6A, right
panel). Similarly, SBC-2 cells (SBC-2-CXCR1, SBC-2-CXCR2 or
SBC-2-control) treated with CXCL-8 (10ngml
 1) induced ERK1/2
phosphorylation and PD98059 treatment suppressed the activation
(data not shown).
To specifically assess the role of the ERK1/2 MAP kinase
pathway in growth, cells were treated with 20mM PD98059±CXCL-
8 in serum-free medium and growth was determined by MTT
assay. Our results clearly showed a decrease in cell growth of
CXCR1 or CXCR2 overexpressing A375P melanoma cells on
treatment with the inhibitor (Figure 6B). Similarly, pretreatment of
cells with PD98059 also significantly reduced CXCL-8-induced
migration (Figure 6C). Similar results were observed in SBC-2-
transfected cells (data not shown) Together, these results
demonstrate that overexpression of CXCR1 or CXCR2 in SBC-2
and A375P melanoma cells leads to CXCL-8-induced activation
of ERK1/2 MAP kinase, which facilitates increased cell growth
and motility.
DISCUSSION
CXCR1 and CXCR2 are overexpressed on melanoma cells (Li et al,
2002, 2003; Varney et al, 2003), but their precise functional role in
human melanoma progression is not well established. In this
study, we demonstrated the functional significance of CXCR1 and
CXCR2 expression in melanoma growth, tumourigenesis, motility
and invasion. Our data showed that either of the receptors
provided a growth advantage to melanoma cells and regulated
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Figure 4 Overexpression of CXCR1 and CXCR2 affect in vitro
melanoma cell growth. SBC-2 (5000 cells per well) (A) and A375P cells
(1000 cells per well) (B) in a 96-well plate were cultured in media with
(1.25%) or without serum. Cellular growth was determined at 72h by MTT
assay. Growth increase was calculated as percent (%)¼[{(A/B)–1} 100],
where A and B are the absorbance of treated (CXCL-8 stimulated) and
untreated cells (media alone), respectively. The values are mean percent
inhibition of growth±s.e.m.
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Moreover, an increase in chemotaxis and chemoinvasion of human
melanoma cells expressing CXCR1 or CXCR2 on stimulation with
CXCL-8 was also observed. In addition, our data demonstrated
that the CXCL-8-induced and CXCR1- or CXCR2-dependent
modulation of melanoma cell proliferation and migration was
mediated through the ERK1/2 MAP kinase pathway.
It is of great interest that the overexpression of CXCR1 or
CXCR2 in SBC-2, a non-tumourigenic cell line induced tumour
formation. Our previous studies have demonstrated that upregula-
tion of CXCL-8 expression by ultraviolet rays or ectopic expression
of CXCL-8 enhanced tumourigenesis in SBC-2 cells (Singh et al,
1995). Although the tumour incidence was identical when A375P-
transfected cells were injected in nude mice, the tumours in
A375P-CXCR1- and A375P-CXCR2-injected mice grew twice as
larger than the control-injected mice. Therefore, the fact that
tumour growth was induced and enhanced by overexpression of
CXCR1 or CXCR2 in melanoma cells suggests the importance of
CXCR1 and CXCR2 as key determinants of melanoma tumour-
igenesis and growth. Additional support is provided by the
observation that tumours in SBC-2 (SBC-2-CXCR1 and SBC-2-
CXCR2) and A375P (A375P-CXCR1 and A375P-CXCR2) groups
had increased tumour cell proliferation and survival, further
suggesting the importance of CXCR1 and CXCR2 in the regulation
of phenotypes associated with melanoma growth. These results
strengthen our previous report that modulation of CXCL-8
expression in melanoma cells enhances tumour growth and
metastasis (Singh et al, 1994; Singh and Varney, 1998).
Our previous results have demonstrated that CXCL-8 is a
paracrine and autocrine angiogenic factor (Li et al, 2003, 2005) and
CXCL-8-mediated angiogenesis is an important step in melanoma
growth. We hypothesised that this process might be augmented in
both groups. Our results show that tumour vascularisation was
increased in SBC-2 (SBC-2-CXCR1 and SBC-2-CXCR2) and A375P
(A375P-CXCR1 and A375P-CXCR2) groups of mice compared with
their respective control mice. The observed increase in neovascu-
larisation was similar to enhanced tumourigenesis and cell
proliferation in vivo. Hence, once again our data emphasise the
importance of CXCR1 and CXCR2 expression in melanoma cells.
Interestingly, our data also demonstrated a greater invasive
potential of SBC-2 and A375P cells expressing CXCR1 or CXCR2 as
compared to control cells. Differential roles of CXCR1 and CXCR2
in endothelial cell migration have been reported previously (Li
et al, 2002, 2003). It was shown that the migration of CXCR1- and
CXCR2-expressing endothelial cells is predominantly mediated
through CXCR2 (Addison et al, 2000; Loukinova et al, 2000;
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Figure 5 CXCR1 and CXCR2 overexpression enhances cell motility and invasion. SBC-2 and A375P cells expressing CXCR1 or CXCR2 were seeded on
non-coated or Matrigel-coated membranes for motility (A and B) and invasion (C and D) assays, respectively, and incubated for 24h. Serum-free medium
containing 10ngml
 1 CXCL-8 was added to the lower chamber. The cells that did not migrate through the Matrigel and/or pores in the membrane were
removed, and cells on the other side of the membrane were stained and photographed at 200  magnification. Cells were counted in 10 random fields
(200 ) and expressed as the average number of cells per field of view. The values are number of migrated cells±s.e.m. This is a representative of three
experiments done in triplicate. *Significantly different from control CXCL-8-treated cells (Po0.05).
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sSchraufstatter et al, 2001; Heidemann et al, 2003). On the other
hand, a recent report suggests that in melanoma cells, CXCL-8-
mediated chemotaxis is mainly mediated through CXCR1
(Ramjeesingh et al, 2003). We, however, did not observe any
significant differences in CXCL-8-dependent motility and invasion
between CXCR1- or CXCR2-overexpressing cells. This is consistent
with our previous observation, where we showed that neutralisation of
either CXCR1 or CXCR2 in vitro inhibits microvascular endothelial
cell migration (Li et al, 2003, 2005). Cumulatively, our findings
support that overall growth of the tumour depends on several factors
including the rate of tumour cell proliferation, survival and
vascularisation of the tumour tissue along with the invasive capacity
of the tumour cells (Jain et al, 1998; O’Hayre et al, 2008).
Here, we have also demonstrated that overexpression of CXCR1
or CXCR2 in CXCL-8-expressing melanoma cells potentiates
ERK1/2 MAP kinase signalling. However, we did not observe a
difference in ERK1/2 phosphorylation between melanoma cells
expressing CXCR1 or CXCR2, which further suggests the involve-
ment of both receptors in the MAPK pathway. Furthermore, our
study demonstrated that when the melanoma cells were incubated
with an ERK1/2 inhibitor, CXCL-8-enhanced proliferation and
migration was decreased. The MAP kinase signalling pathway is
important for controlling various cellular functions such as growth
and migration (Widmann et al, 1999; Kampen et al, 2000). The
ERK1/2 MAP kinase pathway is constitutively activated in most
melanoma cells, where it plays a major role in mediating their
survival and proliferation (Hue et al, 2005). The importance of
ERK1/2 activation in melanoma progression has also been
reported (Zhuang et al, 2005).
In conclusion, our results suggest that CXCR1 and CXCR2 play
important roles in the regulation of human melanoma tumourigen-
esis and progression. Ectopic expression of CXCR1 or CXCR2 confers
a more aggressive phenotype to melanoma cells. Moreover, CXCR1
and CXCR2 are implicated in tumour growth by directly enhancing
tumour cell properties, thus indicating the possibility of manipulating
CXCR1 and CXCR2 for future therapeutic intervention.
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